DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference ...

Investors might want to bet on MannKind (MNKD) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a cha ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is MannKind (MNKD) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.MannKind is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, ...

Shares of MannKind (MNKD) have been strong performers lately, with the stock up 22.7% over the past month. The stock hit a new 52-week high of $5.93 in the previous session. MannKind has gained 60.2% since the start of the year compared to the 7% move for the Zacks Medical sector and the -0.8% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in an ...

Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpointPatients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual careMore than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza® ...

Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpointPatients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual careMore than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza® ...

17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumpsINHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with e ...

Core Insights - MannKind Corporation announced the presentation of 17-week endpoint results from the INHALE-3 study at the American Diabetes Association's 84th Scientific Sessions on June 22, 2024 [1][2] - The study compares the efficacy and safety of inhaled insulin Afrezza with multiple daily injections (MDI) and insulin pumps in adults with Type 1 diabetes [2] Company Overview - MannKind Corporation focuses on developing and commercializing innovative inhaled therapeutic products for endocrine and orphan lung diseases [3][4] - The company aims to address serious unmet medical needs through its dry-powder formulations and inhalation devices, providing rapid and convenient delivery of medications [4] Study Details - The INHALE-3 study is the largest post-market clinical trial conducted by MannKind in the last decade, with results expected to clarify how inhaled insulin compares to usual care [2] - The symposium will feature various presentations, including study methods, results, and critiques from experts in the field [2]

Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D spaceNon-cash deal includes royalty-free iSPERSE™ technology license in exchange for access to MannKind's Cricket® inhaler DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung di ...

Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D spaceNon-cash deal includes royalty-free iSPERSE™ technology license in exchange for access to MannKind’s Cricket® inhaler DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung d ...